Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

BMRA - Biomerica, Inc. So'nggi Yangiliklar | Finranks

Home

BMRA

B

Biomerica, Inc. (BMRA)

NCM – Real vaqt narxi. Valyuta: USD

2.01

-0.10 (-4.74%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.01

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:04 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first commercial order for Hp Detect™, its Helicobacter pylori (H. pylori) diagnostic stool antigen test, from one of the largest clinical laboratory chains operating across Europe. The initial order is for the United Kingdom market, where Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026.

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized. Disease Burden: The WHO designates H.

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial. CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.

Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution

Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is working with a major healthcare products distributor in Vietnam who will manage the sales and distribution of the product through pharmacies, hospitals, physician's offices, and direct online sales channels.

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025.

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test

IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's inFoods® IBS test, establishing a national Medicare payment rate of $300 under the Clinical Laboratory Fee Schedule (CLFS). The pricing will apply to claims for InFoods IBS tests that Medicare approves and pays with dates of service on or after January 1, 2026.

Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio

Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio

Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection of conditions that are related to the most common cancers and chronic diseases • Rapid, easy-to-use, and cost-effective screening for mass and individual use IRVINE, Calif.

Videolar

No Data

There is no data to display

Press-relizlar

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first commercial order for Hp Detect™, its Helicobacter pylori (H. pylori) diagnostic stool antigen test, from one of the largest clinical laboratory chains operating across Europe. The initial order is for the United Kingdom market, where Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026.

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized. Disease Burden: The WHO designates H.

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial. CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.

Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution

Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is working with a major healthcare products distributor in Vietnam who will manage the sales and distribution of the product through pharmacies, hospitals, physician's offices, and direct online sales channels.